Código QR

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib

BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET). This study aims to investigate the safety profiles of sunitinib through data mining of the US...

ver descrição completa

Na minha lista:
Principais autores: Xusheng Zhang, Xiuli Ren, Tianyu Zhu, Wanjin Zheng, Chengwu Shen, Cuicui Lu
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-07-01
Colecção:Frontiers in Pharmacology
Assuntos:
sunitinib
FDA adverse event reporting system
disproportionality analyses
pharmacovigilance
adverse event
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fphar.2024.1407709/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados